Moderna stock: Goldman Sachs lifts target for Moderna stock to USD 137.00

Published on 10/19/2026 at 15:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Moderna hosts an investor webcast on October 24, 2026. Moderna stock costs EUR 192.12 on October 19, 2026, up 0.17 percent versus the Xetra close.

Analyst target and timing

Goldman Sachs adjusted its Moderna target from USD 120.00 to USD 137.00 on October 15, 2026.
Moderna will host an investor webcast on October 24, 2026.
Moderna stock costs EUR 192.12 at Lang & Schwarz on October 19, 2026 at 3:13 p.m. CEST, 0.17 percent above the Xetra close of October 16, 2026.
Moderna had a P/E of minus 27.32 and a market capitalization of USD 87.0 billion as of October 16, 2026.

Aquarellmalerei der Cambridge-Skyline mit modernen Forschungsgebäuden am Charles River — Moderna Inc. (US60770K1034) präsentiert eine stimmungsvolle Aquarell-Ansicht der Cambridge-Skyline mit modernen Biotech-Forschungsgebäuden am Flussufer, Illustration mit AI erstellt.

Goldman Sachs maintained its Neutral rating on Moderna and lifted its price target from USD 120.00 to USD 137.00 on October 15, 2026, according to GuruFocus. The target increase puts the analyst view 36.69 percent below the EUR 192.12 Lang & Schwarz price only if currencies are mixed, so no cross-currency target distance is used. Moderna stock was trading at EUR 192.12 at Lang & Schwarz on October 19, 2026 at 3:13 p.m. CEST, 0.17 percent above the Xetra close of October 16, 2026 at EUR 191.80.

October 24 brings a test

Moderna will host an investor webcast on October 24, 2026, alongside presentations of Phase 3 melanoma data at the European Society for Medical Oncology congress. The event date and presentation schedule were reported by Stock Titan. The scheduled presentation gives investors a dated clinical milestone without turning the analyst target into a forecast.

Revenue remains the counterweight

Moderna reported USD 145.00 million of revenue for the second quarter of 2026, up 2.00 percent from USD 142.00 million a year earlier. Net loss was USD 782.00 million, an improvement of USD 43.00 million, or 5.00 percent, from the prior-year quarter, according to Yahoo Finance. The figures keep the upcoming clinical readout tied to a business that was still loss-making in the latest reported period.

Price position and valuation

On the Nasdaq, Moderna last traded at USD 218.01 on October 16, 2026 at 4:00 p.m. ET. Its 52-week range was USD 22.28 to USD 242.29 on that date, leaving the Nasdaq price 10.02 percent below the high. The same quote showed volume of 21,334,738 shares against an average of 19,101,471.

Moderna's market capitalization was USD 87.0 billion and its P/E was minus 27.32 as of October 16, 2026. The company profile identifies Moderna as a Healthcare biotechnology company with Nasdaq listing and ticker MRNA.

Comparison with peers

Moderna Inc. (Nasdaq, USD): plus 0.17 percent, P/E minus 27.32, market capitalization USD 87.0 billion.

BioNTech (Nasdaq, USD): minus 2.76 percent, P/E minus 11.54, market capitalization USD 22.0 billion.

Pfizer (NYSE, USD): plus 0.48 percent, P/E 39.09, market capitalization USD 168.6 billion.

Trading stays close to the Xetra base

The euro quotation was 0.17 percent above the Xetra close named above, while the Nasdaq price and 52-week range provide separate dollar benchmarks. The further course of trading is shown by the continuously updated real-time quote of Moderna stock.